Gilead Sciences Inc. [NASDAQ: GILD] stock went on an upward path that rose over 0.65% on Monday, amounting to a one-week price decrease of less than -2.38%. The company report on November 3, 2020 that European Medicines Agency Validates Marketing Application for Filgotinib for the Treatment of Ulcerative Colitis.
— Application Based on Results from Pivotal Phase 2b/3 SELECTION Trial –.
Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & Nasdaq: GLPG) today announced that the application for a new indication to the approved license for filgotinib 200 mg, an oral JAK1 preferential inhibitor, has been validated and is now under evaluation by the European Medicines Agency (EMA). The proposed indication is for the treatment of adults with moderately to severely active ulcerative colitis (UC) who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent.
Over the last 12 months, GILD stock dropped by -9.48%. The one-year Gilead Sciences Inc. stock forecast points to a potential upside of 21.52. The average equity rating for GILD stock is currently 2.50, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $73.86 billion, with 1.26 billion shares outstanding and 1.25 billion shares in the current float. Compared to the average trading volume of 9.87M shares, GILD stock reached a trading volume of 9308898 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Gilead Sciences Inc. [GILD]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for GILD shares is $74.58 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on GILD stock is a recommendation set at 2.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
UBS have made an estimate for Gilead Sciences Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on October 28, 2020. While these analysts kept the previous recommendation, Jefferies raised their target price to Buy. The new note on the price target was released on September 30, 2020, representing the official price target for Gilead Sciences Inc. stock. Previously, the target price had yet another raise to $88, while Maxim Group analysts kept a Buy rating on GILD stock. On July 31, 2020, analysts decreased their price target for GILD shares from 87 to 76.
The Average True Range (ATR) for Gilead Sciences Inc. is set at 1.39, with the Price to Sales ratio for GILD stock in the period of the last 12 months amounting to 3.19. The Price to Book ratio for the last quarter was 4.08, with the Price to Cash per share for the same quarter was set at 14.99. Price to Free Cash Flow for GILD in the course of the last twelve months was 14.88 with Quick ratio for the last quarter at 2.20.
GILD Stock Performance Analysis:
Gilead Sciences Inc. [GILD] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -2.38. With this latest performance, GILD shares dropped by -5.85% in over the last four-week period, additionally sinking by -26.04% over the last 6 months – not to mention a drop of -9.48% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for GILD stock in for the last two-week period is set at 30.29, with the RSI for the last a single of trading hit 26.88, and the three-weeks RSI is set at 32.84 for Gilead Sciences Inc. [GILD]. The present Moving Average for the last 50 days of trading for this stock 63.32, while it was recorded at 58.79 for the last single week of trading, and 70.95 for the last 200 days.
Insight into Gilead Sciences Inc. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Gilead Sciences Inc. [GILD] shares currently have an operating margin of +22.22 and a Gross Margin at +79.06. Gilead Sciences Inc.’s Net Margin is presently recorded at +24.13.
Return on Total Capital for GILD is now 10.25, given the latest momentum, and Return on Invested Capital for the company is 11.81. Return on Equity for this stock inclined to 24.53, with Return on Assets sitting at 8.60. When it comes to the capital structure of this company, Gilead Sciences Inc. [GILD] has a Total Debt to Total Equity ratio set at 112.40. Additionally, GILD Total Debt to Total Capital is recorded at 52.92, with Total Debt to Total Assets ending up at 41.08. Long-Term Debt to Equity for the company is recorded at 100.87, with the Long-Term Debt to Total Capital now at 47.49.
Reflecting on the efficiency of the workforce at the company, Gilead Sciences Inc. [GILD] managed to generate an average of $456,441 per employee. Receivables Turnover for the company is 6.46 with a Total Asset Turnover recorded at a value of 0.36.Gilead Sciences Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.20 and a Current Ratio set at 2.30.
GILD Stock EPS
With the latest financial reports released by the company, Gilead Sciences Inc. posted 1.3/share EPS, while the average EPS was predicted by analysts to be reported at 1.67/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -22.20%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for GILD. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Gilead Sciences Inc. go to 0.06%.
Gilead Sciences Inc. [GILD] Insider Position Details
There are presently around $57,833 million, or 81.90% of GILD stock, in the hands of institutional investors. The top three institutional holders of GILD stocks are: CAPITAL RESEARCH GLOBAL INVESTORS with ownership of 125,356,882, which is approximately 30.604% of the company’s market cap and around 0.41% of the total institutional ownership; BLACKROCK INC., holding 115,834,270 shares of the stock with an approximate value of $6.74 billion in GILD stocks shares; and VANGUARD GROUP INC, currently with $6.09 billion in GILD stock with ownership of nearly -2.129% of the company’s market capitalization.
Positions in Gilead Sciences Inc. stocks held by institutional investors increased at the end of October and at the time of the October reporting period, where 721 institutional holders increased their position in Gilead Sciences Inc. [NASDAQ:GILD] by around 87,627,384 shares. Additionally, 873 investors decreased positions by around 95,356,924 shares, while 159 investors held positions by with 811,563,110 shares. The mentioned changes placed institutional holdings at 994,547,418 shares, according to the latest SEC report filing. GILD stock had 126 new institutional investments in for a total of 3,555,913 shares, while 184 institutional investors sold positions of 14,474,282 shares during the same period.